Researchers have discovered a “new technique” to treating eczema.
ECZEMA breaks down the skin’s natural barrier, allowing bacteria, irritants, and allergens to access places that are intended to be off-limits, resulting in an inflammatory response.
Eczema, more especially atopic dermatitis, affects the majority of people before they reach the age of five. Dry, itchy skin is one of the symptoms. “Red to brownish-grey patches” might form on the skin, according to the Mayo Clinic. Small, raised pimples may also appear in certain persons, leaking fluid and crusting over when scratched.
It’s fairly uncommon for the skin to thicken, swell, crack, or become scaly.
This chronic skin problem can go away for a few years before reappearing.
The Granzyme B enzyme is a crucial enzyme that leads to eczema, according to researchers from the University of British Columbia.
Dr. David Granville noted, “Proteins between cells in our skin hold them closely together.”
“In some inflammatory disorders, such as eczema, Granzyme B is released by cells and eats away at those proteins,” explained the professor at the university’s college of medicine.
This is supposed to cause “bonds to weaken” and “additional inflammation and itching of the skin.”
The researchers observed that “knocking down Granzyme B by genetic alteration, or suppressing it with a topical gel” can “significantly” lessen the severity of eczema.
Granzyme B inhibition could help protect the skin barrier from injury.
“Previous research had revealed that Granzyme B levels associated with the degree of itching and disease severity in patients with atopic dermatitis,” Dr Granville continued.
“Our findings show that topical Granzyme B inhibitors could be utilized to treat eczema and other kinds of dermatitis,” says the researcher.
Corticosteroid creams are a frequent treatment for eczema, although they might thin the skin if used for a long time.
Thin skin is thought to be more vulnerable to injury and infection, which is why researchers are looking at new therapeutic options like targeting the Granzyme B enzyme.
Dr. Chris Turner, the study’s lead author, had some thoughts on the subject.
“Blocking Granzyme B with a gel or lotion could have fewer, if any, negative effects and circumvent the itch-scratch cycle, making flare-ups less severe,” Dr Turner added.
A commercially viable Granzyme B therapy is still a long way off.
Researchers, on the other hand, observe. “Brinkwire News in Condensed Form.”